Inogen, Inc (NASDAQ:INGN) at present has an Average Broker Rating of 1.43. The ABR rank within the industry stands at 24. This number is based on the 7 sell-side firms polled by Zacks.
Each brokerage due diligence report carries with it some form of recommendation. The brokerage firms may use nonstandard lingo for their rating systems (like saying Outperform instead of Buy), but they can all be properly sorted into our 5 level classification system that is now the industry standard. Each of the 5 classifications has a value associated with it to assist compute the ABR.
As the name indicates the ABR will show you the Average of Brokerage Recommendations on a given stock. The benefit is that you quickly get a snapshot of where Wall Street stands on a stock without having to read a mountain of due diligence reports.
Broker recommendations are made by brokerage firms (for example, JP Morgan) and are not an outright recommendation to buy or sell a share, but instead give an indication of how the analyst thinks the firm will perform relative to its sector. Their recommendations are issued over a particular stage of time. The recommendations provided in the Research Centre are shown on a 75 day rolling basis. Each brokerage company has its own way of rating that may make it hard to compare analyst recommendations between the brokerage houses.
For example, at one brokerage “buy” may be the strongest recommendation, while at another “buy” could be second to a “strong buy” rating. The second-highest ratings also have a number of nonstandard alternate names: “accumulate”, “outperform”, “moderate buy” or “overweight”.
Analysts on a consensus basis are expecting that the stock will reach $244.2 within the year.
As we sail into the second half of the calendar year, investors may be viewing to see what has gone right and what has gone wrong so far this year. Making needed adjustments to some holdings may assist position investors for the next couple of quarters. Being able to cut the riskier losers and take some profits from winners may assist solidify the stock portfolio. As we run through the next round of firm earnings reports, investors will be keeping a close eye on the data that is reported. Investors may be viewing to buy companies that continue to post beats on the earnings front, and cut ties with ones that are not hitting their marks.
Most recently Inogen, Inc (NASDAQ:INGN) posted quarterly earnings of $0.73 which compared to the sell-side estimates of 0.52. The stock’s 12-month trailing EPS stands at $2.17. Shares have moved $-34.91 over the past month and more recently, $-28.62 over the past week heading into the earnings announcement. There are 6 broker projections that were taken into consideration from respected brokerage firms.
When getting into the markets, most investors realize that riskier stocks may have an increased potential for higher returns. If investors decide to take a chance on some of these stocks, they may want to employ some standard procedures to assist manage that exposure. This may involve creating a diversified stock portfolio. Mixing up the portfolio with stocks from nonstandard sectors, market caps, and growth potential, may be the right move. In general, the goal is to maximize returns in accordance with the individual’s specific exposure profile. It should be obvious that no matter how well rounded the portfolio is, there are always risks in the equity markets. Having a sound plan before investing can assist ease the burden of farsighted that markets can from time to time do crazy things without any rhyme or reason.
Buy Ratings
6 analysts rate Inogen, Inc a Buy or Strong Buy, which is 85.71% of all the broker ratings.
Earnings
Research analysts are predicting that Inogen, Inc (NASDAQ:INGN) will report earnings of $0.26 per share when the company issues their next quarterly report. This is the consensus EPS number according to data from Zack’s Research.
Inogen, Inc (NASDAQ:INGN) closed the last session at $137.97 and sees an average of 572378.63 shares trade hands in each session. The 52-week low of the stock stands at $114.22 while the current level stands at 14.08% of the 52-week High-Low range. Looking extra out we can see that the stock has moved -40.96% over the past 12 weeks and 15.86% year to date.
Active investors are typically interested in the factors that drive share price movements. Buying an individual stock means that you own a piece of the firm. The hope is that the firm does very well and becomes highly profitable. A profitable firm may decide to do various things with the profits. They may reinvest profits back into the business, or they may single out to pay shareholders dividends from those earnings. Sometimes stocks may eventually become undervalued or overvalued. Spotting these trends may lead to extra examination or the underlying fundamentals of the firm. A firm that continues to disappoint on the earnings front may have some issues that are required to be addressed. It is highly necessary to make sure all the due diligence is done on a stock, especially if the investor is heavily weighted on the name. Sometimes earnings reports may be good, but the share price does not reflect that. Having a good understanding of the entire picture may assist investors better travel the winding equity market road.
This article is informational purposes only and should not be considered a recommendation to buy or sell the stock.
